Sickness Evaluation at Altitude With Acetazolamide at Relative Doses

Completed · Phase 1

Conditions studied: Acute Mountain Sickness

In brief

The specific aim of this study is to evaluate whether acetazolamide 125mg daily is no worse than acetazolamide 250mg daily in decreasing the incidence of acute mountain sickness (AMS) in travelers to high altitude. The study population is hikers who are ascending at their own rate under their own power in a true hiking environment at the White Mountain Research Station, Owen Valley Lab (OVL) and Bancroft Station (BAR), Bancroft Peak, White Mountain, California

Key facts

Study ID

NCT03828474

Run by

Stanford University

People needed

108

Starts

2019-08-09

Expected to finish

2019-09-29

Last updated by the study team

2019-10-22

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Able to complete moderate hike at altitude
• Live at elevation < 4,000 ft
• Able to arrange own transportation to study site
• Available for full study duration (Friday night - Sunday morning)

You may not qualify if…

• Pregnancy
• Slept at altitude > 4,000 ft within 1 week of study
• Allergy to acetazolamide or sulfa drugs
• NSAIDs, acetazolamide, or corticosteroids within 48 hours prior to study start
• History of severe anemia, severe heart disease, advanced COPD/emphysema or sickle cell disease

Where it is running

• White Mountain Research Center — Bishop, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.